Homology Medicines Third Quarter 2023 Earnings: US$0.57 loss per share (vs US$0.59 loss in 3Q 2022)

Homology Medicines (NASDAQ:FIXX) Third Quarter 2023 Results

Key Financial Results

• Net loss: US$33.0m (loss narrowed by 2.3% from 3Q 2022).
• US$0.57 loss per share (improved from US$0.59 loss in 3Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Homology Medicines Earnings Insights

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 16% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 43% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 5 warning signs for Homology Medicines you should be aware of, and 1 of them is a bit unpleasant.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.